carbamazepine metabolism
Recently Published Documents


TOTAL DOCUMENTS

27
(FIVE YEARS 2)

H-INDEX

10
(FIVE YEARS 0)

2021 ◽  
Vol 177 ◽  
pp. 106785
Author(s):  
Yu-Xin Fan ◽  
Zheng Zhang ◽  
Jing-Ru Meng ◽  
Sun-Jun Yin ◽  
Ping Wang ◽  
...  

2021 ◽  
Vol 173 ◽  
pp. 106615
Author(s):  
Gui-Xin Zhao ◽  
Zheng Zhang ◽  
Wen-Ke Cai ◽  
Ming-Li Shen ◽  
Ping Wang ◽  
...  

2020 ◽  
Author(s):  
Gui-Xin Zhao ◽  
Zheng Zhang ◽  
Wen-Ke Cai ◽  
Ming-Li Shen ◽  
Ping Wang ◽  
...  

AbstractBackground and objectiveCYP3A4 (rs2242480), CYP3A5 (rs776746) and SCN1A (rs3812718 and rs2298771) gene polymorphisms were previously indicated to be associated with carbamazepine (CBZ) metabolism and resistance in epilepsy. However, previous studies regarding the effects of these polymorphisms still remain controversial. Therefore, we performed a meta-analysis to evaluate whether the four polymorphisms are associated with CBZ metabolism and resistance.MethodsThe PubMed, EMBASE, Cochrane library, Chinese National Knowledge Infrastructure, Chinese Science and Technique Journals Database, China Biology Medicine disc and Wan fang Database were searched up to January 2020 for appropriate studies regarding the association of rs2242480, rs776746, rs3812718 and rs2234922 polymorphisms with metabolism and resistance to CBZ. The meta-analysis was conducted by Review Manager 5.3 software.ResultsEighteen studies involving 2574 related epilepsy patients were included. Significant associations between CYP3A4 rs2242480, CYP3A5 rs776746 and SCN1A rs3812718 polymorphisms and plasma concentrations of CBZ were observed. Additionally, SCN1A rs3812718 polymorphism was significantly associated with CBZ resistance. However, no association was observed between SCN1A rs2298771 polymorphism and metabolism and resistance to CBZ.ConclusionThe CYP3A4 rs2242480, CYP3A5 rs776746 and SCN1A rs3812718 polymorphisms may play important roles in metabolism and resistance to CBZ, while SCN1A rs2298771 polymorphism is not associated with CBZ in epilepsy. These findings would improve the individualized therapy of epileptic patients in clinics.


2019 ◽  
Vol 41 (6) ◽  
pp. 1414-1428 ◽  
Author(s):  
Gui-Xin Zhao ◽  
Ming-Li Shen ◽  
Zheng Zhang ◽  
Ping Wang ◽  
Chun-Xiang Xie ◽  
...  

Life Sciences ◽  
2019 ◽  
Vol 218 ◽  
pp. 314-323 ◽  
Author(s):  
Tianjing Ren ◽  
Mengbi Yang ◽  
Min Xiao ◽  
Junjie Zhu ◽  
Wen Xie ◽  
...  

2016 ◽  
Vol 30 (1) ◽  
pp. 16-21 ◽  
Author(s):  
Chahra Chbili ◽  
Neila Fathallah ◽  
Aicha Laouani ◽  
Manel Nouira ◽  
Anis Hassine ◽  
...  

2015 ◽  
Vol 37 (12) ◽  
pp. 991-997 ◽  
Author(s):  
Chahra Chbili ◽  
Neila Fathallah ◽  
Manel Nouira ◽  
Aicha Laouani ◽  
Anis Hassine ◽  
...  

2015 ◽  
Vol 16 (2) ◽  
pp. 93-99 ◽  
Author(s):  
Dragana Dragas Milovanovic ◽  
Ivan Radosavljevic ◽  
Marija Radovanovic ◽  
Jasmina R. Milovanovic ◽  
Slobodan Obradovic ◽  
...  

Abstract Carbamazepine exhibits significant inter-individual variability in its efficacy and safety, which leads to unpredictable therapy outcomes for the majority of patients. Although its complex biotransformation depends on CYP3A5 activity, evidence of association between carbamazepine treatment outcomes and CYP3A5 functional variations remains inconclusive. The aim of the present study was to investigate the distribution of two of the functionally important CYP3A5 variants *2 and *3 as well as their effects on carbamazepine dose requirements, plasma concentrations and clearance in a Serbian population. The study involved 40 paediatric epileptic patients on steady-state carbamazepine treatment. Genotyping was conducted using the PCR-RFLP method, and carbamazepine plasma concentrations were determined using the HPLC method. CYP3A5*2 and *3 polymorphisms were found at frequencies of 0.0% and 97.5%, respectively, which corresponds well to previously published data for Caucasians. No differences in CYP3A5*3 allele frequencies were detected among epileptic patients in comparison to healthy volunteers within similar ethnic populations (p>0.08), indicating that CYP3A5 polymorphism does not represent a risk factor for epilepsy development. There was an observed tendency towards lower dosage requirements (mean±SD: 15.06±4.45 mg/kg vs. 18.74±5.55 mg/kg; p=0.26), higher plasma concentrations (mean±SD: 0.45±0.13 mg/kg vs. 0.38±0.03 mg/kg; p=0.47) and lower clearance (mean±SD: 0.14±0.05 mg/kg vs. 0.15±0.01 mg/kg; p=0.79) of carbamazepine in homozygous carriers of CYP3A5*3/*3 compared to heterozygous CYP3A5*1A/*3 Serbians. Because these genotype groups did not differ significantly in terms of their carbamazepine pharmacokinetics parameters, the proposed effects of CYP3A5*3 on carbamazepine metabolism could not be confirmed.


Sign in / Sign up

Export Citation Format

Share Document